Apr 13, 2023 08:04AM
Oct 24, 2022 10:55AM
Sep 27, 2022 12:24PM
Aug 22, 2022 08:30AM
Jul 18, 2022 08:30AM
Jun 22, 2022 08:30AM
Mar 2, 2022 08:30AM RegeneRx Provides Regulatory Update Regarding RGN-259
Jan 25, 2022 08:30AM
Dec 17, 2021 09:43AM
Nov 29, 2021 08:30AM
Oct 29, 2021 11:08AM
Jul 22, 2021 08:30AM
Jul 14, 2021 08:07AM
May 14, 2021 08:30AM RegeneRx Joint Venture Reports Positive Results from ARISE-3 Clinical Trial Using RGN-259 to Treat Dry Eye Syndrome
Mar 18, 2021 06:51AM
Nov 9, 2020 09:28AM
Oct 28, 2020 08:30AM
Aug 31, 2020 08:30AM
May 27, 2020 11:33AM
May 14, 2020 05:30AM
Sep 30, 2019 09:34AM RegeneRx Partner Updates on ARISE-3 Clinical Trial
May 29, 2019 07:40AM
May 28, 2019 10:58AM
May 13, 2019 09:47AM
Mar 26, 2019 09:13AM
Mar 21, 2019 08:30AM
Feb 27, 2019 02:11PM
Feb 12, 2019 07:42AM Regenerx Biopharma (RGRX) U.S. JV Commences Key Phase 3 Dry Eye Clinical Trial with RGN-259
Feb 12, 2019 07:38AM
Jan 4, 2019 11:00AM
Oct 29, 2018 10:16AM
Sep 6, 2018 07:33AM
Aug 2, 2018 08:30AM
Jul 16, 2018 09:25AM
May 2, 2018 08:30AM ReGenTree Presents Results of a Comparison Study of RGN-259 and Approved Prescription Drugs for Dry Eye Syndrome in a Mouse Model at ARVO
Apr 9, 2018 07:06AM
Apr 9, 2018 07:05AM
Mar 14, 2018 09:17AM
Mar 12, 2018 08:30AM
Mar 2, 2018 11:32AM
Feb 22, 2018 07:54AM
Feb 14, 2018 09:25AM RegeneRx Receives Canadian Patent for Treating Neurological Injury and Damage
Nov 16, 2017 08:31AM
Oct 31, 2017 08:00AM
May 9, 2017 10:00AM
Feb 27, 2017 08:30AM

323,894 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All